Historical record - last NADAC effective date: 4/22/2020
Product Information
REYATAZ 300 MG CAPSULE is a brand product labeled by E.R. Squibb & Sons, L.L.C., priced at $46.9853 per EA under NDC 00003362212. Its NADAC has been published 386 times since Nov 28, 2013.
FDA first approved this application on Jun 20, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the ATAZANAVIR market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
E.R. Squibb & Sons, L.L.C.NDC
00003362212
Classification
Brand
Dosage Form
CAPSULE, GELATIN COATED
Route
ORAL
Effective Date
4/22/2020
Active Ingredients
ATAZANAVIR SULFATEApproval Type
New Drug (NDA)
FDA Application
NDA021567FDA Approved
6/20/2003
TE Code
AB
On Market Since
6/24/2003
Pharmacological Classes
Price Statistics
The NADAC for REYATAZ 300 MG CAPSULE has been published 386 times since Nov 28, 2013, and over the history we have for it it has risen 32.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $46.9853 per EA |
|---|---|
| All-time high | $46.9853 (Apr 14, 2021) |
| All-time low | $35.2036 (Dec 18, 2013) |
| Median price | $46.4820 |
| Average price | $44.2085 |
| Largest weekly change | +7.9% (Jan 8, 2014) |
| Weeks tracked | 386 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+32.5%
Last surveyed Apr 14, 2021 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ATAZANAVIR market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E.R. Squibb & Sons, L.L.C. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ATAZANAVIR market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Protease Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of REYATAZ 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for REYATAZ 300 MG CAPSULE, manufactured by E.R. Squibb & Sons, L.L.C., is $46.9853 per EA (NDC 00003362212), effective Apr 14, 2021.
How has the price of REYATAZ 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for REYATAZ 300 MG CAPSULE has risen 32.5%. It has been tracked across 386 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for REYATAZ 300 MG CAPSULE?
Since Nov 28, 2013, the NADAC for REYATAZ 300 MG CAPSULE has ranged from a low of $35.2036 (Dec 18, 2013) to a high of $46.9853 (Apr 14, 2021), with a median of $46.4820 per EA.
Are there cheaper alternatives to REYATAZ 300 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of REYATAZ 300 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures REYATAZ 300 MG CAPSULE?
REYATAZ 300 MG CAPSULE (NDC 00003362212) is labeled by E.R. Squibb & Sons, L.L.C., and CMS classifies it as a brand product.